A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice

British Journal of Pharmacology

Volumn 155, Issue 5, 2008, Pages 714-721

  Bastos, L F S ^a   Angusti, A ^b   Vilaca M C ^a   Merlo, L A ^a   Nascimento Jr , E B ^a   Rocha, L T S ^a   Godin, A M ^a   Solano, A G R ^a   Jarussophon, S ^b,c   Nunan, E A ^a   Konishi, Y ^b   Coelho, M M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

12S hydroxy 1,12 pyrazolinominocycline; Chelating activity; Chemically modified tetracyclines; Cylinder plate assay; Inflammation; Minocycline; Nociception; Oedema; Pain

Indexed keywords

CARRAGEENAN; FORMALDEHYDE; HYDROXY 1,12 PYRAZOLINOMINOCYCLINE; HYDROXYPYRAZOLINE DERIVATIVE; MINOCYCLINE; PYRAZOLINE DERIVATIVE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BINDING ASSAY; CALCIUM BINDING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; INFLAMMATION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; ROTAROD TEST; SPECTROPHOTOMETRY; STAPHYLOCOCCUS AUREUS; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM; CATIONS, DIVALENT; CHELATING AGENTS; EDEMA; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PAIN; PAIN MEASUREMENT; PYRAZOLES; ROTAROD PERFORMANCE TEST; STAPHYLOCOCCUS AUREUS;

EID: 54949116146     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.303     Document Type: Article

References (47)

1. Alano CC, Kauppinen TM, Valls AV, Swanson RA (2006). Minocycline inhibits poly (ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103: 9685-9690.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN et al. (1996). A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019.
4. Bastos LFS, Merlo LA, Rocha LTS, Coelho MM (2007). Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol 576: 171-179.
5. Bazin MJ, Shi H, Delaney J, Kline B, Zhu Z, Kuhn C et al. (2007). Efficient use of the iron ortho-nitrophenylporphyrin chloride to mimic biological oxidations of dimethylaminoantipyrine. Chem Biol Drug Des 70: 354-359.
6. British Pharmacopoeia (2007). British Pharmacopoeial Comission. The Stationery Office: London.
7. 2+-sensing receptor from bovine parathyroid. Nature 366: 575-580.
8. Chichorro JG, Lorenzetti BB, Zampronio AR (2004). Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats. Br J Pharmacol 141: 117-184.
9. Chow AK, Cena J, Schulz R (2007). R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152: 189-205.
10. D'Agostino P, Ferlazzo V, Milano S, La Rosa M, Di Bella G, Caruso R et al. (2001). Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int Immunopharmacol 1: 1765-1776.
11. Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G et al. (2004). Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 186: 248-251.
12. Gabler WL, Creamer HR (1991). Suppression of human neutrophil functions by tetracyclines. J Periodont Res 26: 52-58.
13. Gordon CJ (1990). Thermal biology of the laboratory rat. Physiol Behav 47: 963-991.
14. Goulden V, Glass D, Cunliffe WJ (1996). Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134: 693-695.
15. Grove DC, Randall WA (1955). The tetracyclines (chlortetracycline, oxytetracycline and tetracycline). In: Welch H, Martí-Ibáñez F (ed). Assay Methods of Antibiotics: a Laboratory Manual. Medical Encyclopedia Inc.: New York, pp 48-56.
16. Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007). Matrix metalloproteinases inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498.
17. Hunskaar S, Hole K (1987). The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 30: 113-114.
18. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W (2004). Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 27: 314-318.
19. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW et al. (2005). Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54: 1559-1565.
20. Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF et al. (2005). Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115: 71-83.
21. Lertvorachon J, Kim J, Soldatov DV, Boyd J, Roman G, Cho SJ et al. (2005). 1-12-Substituted tetracyclines as antioxidant agents. Bioorg Med Chem 13: 4627-4637.
22. Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D (2007). Cytokine profiles during carrageenan-induced inflammatory hyperalgesia in rat muscle and hind paw. J Pain 8: 127-136.
23. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M et al. (2007). TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA 104: 13525-13530.
24. Moore PK, Oluyomi AO, Babbedge RC, Wallace P, Hart SL (1991). L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 102: 198-202.
25. Nikodemova M, Duncan ID, Watters J (2006). Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IκBα degradation in a stimulus-specific manner in microglia. J Neurochem 96: 314-323.
26. α/βII. J Biol Chem 282: 15208-15216.
27. 2 production. J Immunol 163: 3459-3467.
28. Pi R, Li W, Lee NTF, Chan HHN, Pu Y, Chan LN et al. (2004). Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 91: 1219-1230.
29. Piao ZG, Cho IH, Park CK, Hong JP, Choi SY, Lee SJ et al. (2006). Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 121: 219-231.
30. Prado W (2001). Involvement of calcium in pain and antinociception. Braz J Med Biol Res 34: 449-461.
31. 2 by minocycline and doxycycline. Biochem Pharmacol 44: 1165-1170.
32. Raghavendra V, Tanga F, DeLeo JA (2003). Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neurophathy. J Pharmacol Exp Ther 306: 624-630.
33. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT et al. (1996). Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118: 829-838.
34. Sánchez AR, Rogers III RS, Sheridan PJ (2004). Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 43: 709-715.
35. Sandler C, Ekokoski E, Lindstedt KA, Vainio PJ, Finel M, Sorsa T et al. (2005). Chemically modified tetracycline (CMT-3) inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. Inflamm Res 54: 304-312.
36. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML et al. (2006). Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res 1085: 57-67.
37. Stone M, Fortin PR, Pacheco-Tena C, Inman RD (2003). Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 30: 2112-2122.
38. Tikka T, Fiebich BL, Goldsteins G, Keinänen R, Koistinaho J (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21: 2580-2588.
39. Tjølsen A, Berge O-G, Hunskaar S, Rosland JH, Hole K (1992). The formalin test: an evaluation of the method. Pain 51: 5-17.
40. Tolomeo M, Grimaudo S, Milano S, La Rosa M, Ferlazzo V, Di Bella G et al. (2001). Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Br J Pharmacol 133: 306-314.
41. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, Mckenzie KK (1987). Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed Proc 46: 118-126.
42. Watkins LR, Maier SF (2003). Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov 2: 973-985.
43. Webster GF, Toso SM, Hegemann L (1994). Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: Involvement of protein kinase C. Arch Dermatol 130: 748-752.
44. White JP, Cantor CR (1971). Role of magnesium in the binding of tetracycline to Escherichia coli ribosomes. J Mol Biol 58: 397-400.
45. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J (1998). Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95: 15769-15774.
46. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J (1999). A tetracycline derivate, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500.
47. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.